Table 7 Summary of the sensitivity analysis

 Percentage of clinical patients who experience ADL episodes per year

70 % (45–90 %)

95 % (90–95 %)

[8, 10–17]

 Frequency of ADL episodes for clinical patients (in absence of MDA)

2 (0–7) per year

4 (0–7) per year

[8, 10–17]

 Average duration of an ADL episode

4 (1–9) days

4 (1–9) days

[8, 10–17]

 Disability weight for symptomatic LF infection

0.11 (0.073–0.157)

0.11 (0.073–0.157)

[40]

 Mean age of the benefit cohorts (years)

Cohort 1: 20 (30)

Cohort 1: 20 (30)

Cohort 2: 20 (30)

Cohort 2: 20 (30)

Cohort 3: 30 (40)

Cohort 3: 30 (40)

 Percentage of patients with ADL seeking treatment per episode

55 % (55–70 %)

55 % (55–70 %)

[8, 11, 14, 44, 46]

India 70 % (70–98 %)

(India 75 % (75–98 %))

 Percentage of chronic disease patients seeking treatment

20 % (20–50 %)

30 % (30–55 %)

[9, 44, 45]

India: 50 % (41–80 %)

India 55 % (48–100 %)

 Average patient medical expenses per ADL episode

+−20 % of baseline value

+−20 % of baseline value

[8, 11, 44–48]

 Average patient medical expenses for chronic disease per year

+−20 % of baseline value

+−20 % of baseline value

[8, 11, 44–48]

 Work days per year

300 (261–365) days

300 (261–365) days

 Percentage of work hours lost per day during an ADL episode

75 % (50–93 %)

75 % (50–93 %)

[12, 14, 16, 87]

 Percentage of work hours lost due to chronic disease

15 % (9–24 %)

19 % (11–31 %)

[12, 43, 45, 46]

 Discount rate

3 % (0–6 %)

3 % (0–6 %)

[59]

 The reduction in transmission experienced by the treated population

Year 1: 50 % (35 %)

Year 1: 50 % (35 %)

[18]

Year 2: 75 % (53 %)

Year 2: 75 % (53 %)

Year 3: 88 % (62 %)

Year 3: 88 % (62 %)

Year 4: 94 % (66 %)

Year 4: 94 % (66 %)

Year 5 95 % (67 %)

Year 5 95 % (67 %)

 Reduction in the frequency of ADL episodes by MDA

50 % (15–88 %)

50 % (15–88 %)

[33, 36, 37].

 Percentage of chronic disease alleviated by MDA

10 % (0–90 %)

15 % (0–69 %)

[20, 30–35]